公开(公告)号：US20170275697A1

公开(公告)日：2017-09-28

申请号：US15159359

申请日：2016-05-19

申请人： Pacific Edge Limited

发明人： David Darling ,  James Miller Suttie ,  Mark Dalphin ,  Laimonis Kavalieris ,  Paul O'Sullivan ,  Satish Kumar

IPC分类号： C12Q1/68 ,  G01N33/50 ,  G01N33/574

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/50 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2800/60

摘要： New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.

公开(公告)号：US10131955B2

公开(公告)日：2018-11-20

申请号：US15159359

申请日：2016-05-19

申请人： Pacific Edge Limited

发明人： David Darling ,  James Miller Suttie ,  Mark Dalphin ,  Laimonis Kavalieris ,  Paul O'Sullivan ,  Satish Kumar

IPC分类号： G01N33/48 ,  C12Q1/6886 ,  G01N33/574 ,  G01N33/50

摘要： New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.

公开(公告)号：US20190203300A1

公开(公告)日：2019-07-04

申请号：US16194956

申请日：2018-11-19

申请人： Pacific Edge Limited

发明人： David Darling ,  James Miller Suttie ,  Mark Dalphin ,  Laimonis Kavalieris ,  Paul O'Sullivan ,  Satish Kumar

IPC分类号： C12Q1/6886 ,  G01N33/574 ,  G01N33/50

CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/50 ,  G01N33/57407 ,  G01N33/57484 ,  G01N2800/60

摘要： New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC.